Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. SYNLAB AG
  6. News
  7. Summary
    SYAB   DE000A2TSL71

SYNLAB AG

(SYAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE: SYNLAB to continue providing COVID-19 testing at UEFA competition matches and UEFA EURO 2020

06/10/2021 | 01:31am EDT
DGAP-News: SYNLAB AG / Key word(s): Contract/Alliance 
SYNLAB to continue providing COVID-19 testing at UEFA competition matches and UEFA EURO 2020 
2021-06-10 / 07:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
SYNLAB AG 
Moosacher Straße 88 
80809 Munich 
Germany 
 
SYNLAB to continue providing COVID-19 testing at UEFA competition matches and UEFA EURO 2020 
 
  . SYNLAB appointed by UEFA as 'UEFA Laboratory Diagnostics Provider 2021/2022' to be responsible for COVID-19 testing 
    for players, officials and venue staff, which is an essential part of UEFA's Return to Play Protocol 
SYNLAB, Europe's leading medical diagnostic services provider, and the existing laboratory diagnostics services 
provider of UEFA, the governing body of European football, has been entrusted to continue providing PCR-testing for 
SARS-CoV-2 at UEFA competition matches for the upcoming football season. As the 'UEFA Laboratory Diagnostics Provider 
2021/2022', SYNLAB will support implementing UEFA's rigorous Return to Play Protocol, to create as the safest possible 
environment for teams, officials, and venue staff. 
With the extension of the partnership, SYNLAB will utilize its broad European laboratory network to provide advanced 
diagnostics for UEFA EURO 2020, testing all 24 teams as well as officials and venue staff at the 11 dedicated match 
sites across Europe. 
Over the course of the 2020/2021 season, SYNLAB has successfully conducted more than 160,000 PCR-tests for UEFA 
competition matches. SYNLAB and its partners will continue to test all players and staff for SARS-CoV-2 ahead of every 
match using the RT-PCR or a medically equivalent testing method. Only persons with negative results will be allowed to 
attend a match and have access to the stadium. 
Mathieu Floreani, CEO of SYNLAB, says: "We are pleased to continue our successful and trusted partnership with UEFA. 
Based on SYNLAB's clear commitment to medical excellence, we will continue to make every effort to leverage our broad 
capabilities across Europe to ensure that testing of the players, officials, and venue staff is implemented in the best 
possible way. Especially in view of UEFA EURO 2020, we are proud to play our part in creating the safest possible 
environment for Europe's unique football event. The tournament will bring joy to millions - if not billions - of 
football fans in Europe and beyond in times of the COVID-19 pandemic." 
Underlining UEFA's commitment to reliable testing procedures and the rigorous Return to Play protocol, Giorgio 
Marchetti, UEFA deputy secretary, adds: "As the fight against the COVID-19 pandemic continues, the health and 
well-being of players, staff, referees and everyone operating in the stadium remains to be our absolute priority. The 
last year has shown that partnering with an industry leader like SYNLAB allows us to ensure that all UEFA competition 
matches are played in an as safe as possible environment. We are looking forward to continuing this successful 
cooperation with SYNLAB". 
For more information: 
Media contact:                           +49 (0) 160 9192 5265 
Florian Brueckner, FTI Consulting        Florian.Brueckner@fticonsulting.com 
Investor contact:                        +49 (0) 170 118 3753 
Mark Reinhard, SYNLAB                    Mark.Reinhard@synlab.com About SYNLAB   . SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medical diagnostic 

services company and offers a full range of innovative and reliable medical diagnostics for patients, practising

doctors, clinics and the pharmaceutical industry. . Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in

human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of

patients and customers. . SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. Around 20,000

employees, including over 1,200 medical experts, as well as a large number of other specialists such as biologists,

chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB carries out 500

million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020. . More information can be found on www.synlab.com -----------------------------------------------------------------------------------------------------------------------

2021-06-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      SYNLAB AG 
              Moosacher Straße 88 
              80809 Munich 
              Germany 
Phone:        +49 1701183753 
E-mail:       ir@synlab.com 
Internet:     www.synlab.com/ 
ISIN:         DE000A2TSL71 
WKN:          A2TSL7 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1205688 
 
End of News   DGAP News Service 
=------------ 

1205688 2021-06-10

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1205688&application_name=news 
 

(END) Dow Jones Newswires

June 10, 2021 01:31 ET (05:31 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL -1.58% 33290.08 Delayed Quote.10.51%
FTI CONSULTING, INC. -1.87% 136.88 Delayed Quote.22.52%
SYNLAB AG -0.70% 17.79 Delayed Quote.0.00%
All news about SYNLAB AG
06/10PRESS RELEASE : SYNLAB to continue providing COVID-19 testing at UEFA competitio..
DJ
06/10SYNLAB  : to continue providing COVID-19 testing at UEFA competition matches and..
EQ
06/07SYNLAB  : Deutsche Bank gives a Buy rating
MD
06/07SYNLAB  : JP Morgan gives a Neutral rating
MD
06/07SYNLAB  : Receives a Buy rating from Jefferies
MD
06/07SYNLAB  : Goldman Sachs gives a Buy rating
MD
06/03SAVILLS  : City sees highest monthly take-up of office space in more than a year
AQ
05/26PRESS RELEASE : SYNLAB and Hospital District of Helsinki and Uusimaa extend part..
DJ
05/26SYNLAB  : and Hospital District of Helsinki and Uusimaa extend partnership for c..
EQ
05/12SYNLAB  : delivers record growth in Q1 2021
EQ
More news
Financials
Sales 2021 3 145 M 3 730 M 3 730 M
Net income 2021 344 M 408 M 408 M
Net Debt 2021 1 779 M 2 109 M 2 109 M
P/E ratio 2021 11,6x
Yield 2021 2,21%
Capitalization 3 953 M 4 687 M 4 688 M
EV / Sales 2021 1,82x
EV / Sales 2022 1,92x
Nbr of Employees 20 000
Free-Float 75,7%
Chart SYNLAB AG
Duration : Period :
SYNLAB AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 22,96 €
Last Close Price 17,79 €
Spread / Highest target 57,4%
Spread / Average Target 29,1%
Spread / Lowest Target 14,1%
EPS Revisions
Managers and Directors
NameTitle
Mathieu Olivier Floreani Chairman-Management Board & CEO
Sami Badarani Chief Financial Officer & Finance Director
David Raymond Ebsworth Chairman-Supervisory Board
Valor Garcia Santiago Chief Medical Officer
Henrik Andreasen Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
SYNLAB AG0.00%4 687
SONIC HEALTHCARE LIMITED17.60%13 525
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.11.72%10 261
NEOGENOMICS, INC.-19.91%5 085
DR. LAL PATHLABS LIMITED37.89%3 538
BURNING ROCK BIOTECH LIMITED17.84%2 846